Curebase and Meru Health Partner for Clinical Research of App-Based Mental Health Treatment Program

Curebase and Meru Health Partner for Clinical Research of App-Based Mental Health Treatment Program

SAN FRANCISCO, September 20, 2022 /PRNewswire/ — Curebase, a company committed to democratizing access to clinical studies, today announced its partnership with Meru Health in a three-year clinical trial to determine the program’s effectiveness. 12-week treatment program from online mental health provider to reduce depression among primary care patients.

The Meru Health Program is an app-based, therapist-guided treatment program for depression, burnout and anxiety. The program under study is a 12-week smartphone-based solution that goes beyond traditional standards of care, including talk therapy and medication.

The study, funded by the National Institute of Health’s Small Business Innovation Research (SBIR) program, will be divided into two phases. In the proof-of-concept phase, 15 patients will follow Meru Health’s treatment program, while another 15 will receive treatment as usual (such as face-to-face therapy, antidepressants, or a combination) under the guidance of their primary care physician. .

Meru Health and Curebase will begin recruiting for this first phase in early fall 2022 and are expected to conclude in spring 2023. Curebase will be responsible for clinical site selection, patient recruitment and data collection.

Curebase’s Decentralized Clinical Trials (DCT) platform enables clinical sites to streamline patient recruitment and consent processes before initiating a clinical study. Once a trial is underway, the Curebase platform optimizes the capture of patient data, whether generated from a patient site visit or remotely via a telemedicine session.

Curebase enables patients to participate in Meru Health research as part of their primary healthcare. For example, during an annual physical exam, a clinician can assess a patient’s mental health, and if symptoms indicate that a person is suffering from depression or general anxiety, the clinician can then refer a patient that he identifies as potentially eligible for this study towards this program. . If the patient passes the screening and clinical admission process, they will be asked to download the app and proceed with registration.

After analyzing the outcomes and processes that were established during the proof-of-concept study, Curebase and Meru Health will collaborate on a randomized controlled trial (RCT) that will include 300 participants and eight primary care clinics across the states. -United.

During the RCT phase, Curebase and Meru Health will collect and analyze ePRO or patient-reported electronic results. After participants complete their treatment, researchers will track their progress for up to a year to determine if there are any lasting benefits for patients in the Meru Health program compared to usual standard treatment.

“Meru Health’s smartphone-based mental health program shows tremendous potential to bring effective and accessible treatment to the growing patient population suffering from depression and anxiety,” said Curebase CEO and Founder. Tom Lemberg. “We are excited to work with Meru Health on clinical research that has the potential to benefit millions of Americans.”

In addition to on-demand clinician support, behavioral mindfulness, and biofeedback practices, Meru Health integrates sleep, nutrition, and social support into its treatment framework. This new app includes built-in functionality for collecting biofeedback data such as heart rate variability via a device attached to the participant’s earlobe.

“Too many people struggling with mental health issues also struggle to access effective treatment and our solution was created to help these people,” said Christian Ranta, founder and CEO of Meru Health. “Curebase is an ideal partner for us, as the company’s DCT platform and support services allow us to focus on the clinical aspects of these trials, while treating participating patients in various locations.

Nearly one in five American adults lives with a mental illness and only half of Americans with mental health issues receive treatment, according to the National Institute of Mental Health. Roughly $280 billion was spent on mental health services in 2020.

About Curebase

At Curebase, our mission is to bring quality medical innovations to patients faster and improve human well-being through more effective clinical studies. We are proving that clinical research can be radically accelerated if we empower physicians around the world to recruit patients from the communities where they live. By applying cutting-edge clinical software and remote study management techniques to the problem, we are reinventing clinical trials and research from the ground up. For more information, please visit www.curebase.com.

About Meru Health

Meru Health is setting the new standard in mental health care with the most comprehensive online solution that combines licensed therapists and psychiatrists, a smartphone treatment program, biofeedback training, anonymous peer support and habit-changing activities for sleep, nutrition and more. The company is committed to providing evidence-based care and has published groundbreaking clinical results with Stanford, Harvard, and UC Davis that show promising clinical effectiveness and long-lasting results that provide a convenient, accessible, and side-effect-free mental health treatment option unlike the standard of care in the United States today. Meru Health partners with leading health insurance providers such as Cigna, Humana, and Moda Health, as well as leading companies that want to provide the best mental health care to their employees or members. For more information, visit www.meruhealth.com and follow us on LinkedIn, Facebook and Twitter.

Media contacts:

Shawn Malloy
[email protected]
315-882-5310

Adam Beeson
Amendola Communications (for Curebase)
847-867-0048

SOURCE Curebase


#Curebase #Meru #Health #Partner #Clinical #Research #AppBased #Mental #Health #Treatment #Program

Leave a Comment

Your email address will not be published.